Kinoxis Therapeutics
Kinoxis Therapeutics is an Australian clinical-stage biotechnology company developing first-in-class therapeutics targeting ALOX15, a key regulator of neuroinflammation and neural excitability in the brain. The company focuses on treatments for agitation, aggression, and chronic pain associated with central nervous system disorders. Its lead candidate, KNX100, is a short-acting ALOX15 inhibitor currently undergoing a Phase 2 clinical trial for acute agitation and aggression in dementia patients. Kinoxis is also advancing KNX101, a long-acting ALOX15 inhibitor for acute and chronic pain management.
No linked organisations yet
We don’t have employment, investment or management links for this one yet.